Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Navitoclax Alone and with Ruxolitinib in Myeloproliferative Neoplasms (Japan)
jRCT2080224824Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of navitoclax in myelofibrosis (MF), polycythemia vera (PV), thrombocythemia and 1 more (2 arms), sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability of navitoclax alone and in combination with ruxolitinib and Pharmacokinetics of navitoclax. Started Aug 2019; status: completed.
02
Drugs
navitoclax
03
Conditions
myelofibrosis (MF)polycythemia vera (PV)thrombocythemiamyeloproliferative disorder (MPD)
Beyond the preview
Go deeper on jRCT2080224824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224824.